The "Upstream" Partner for Combinatorial Success
We enable the next generation of blockbuster therapies by providing the necessary immune substrate. Novastra positions itself as the mandatory partner for assets that require a primed immune system to function.
Unlocking the Potential of Bispecifics & CAR-T
Emerging PD-1/VEGF bispecifics and T-cell engagers excel at "bridging" cells or normalizing vasculature, but they cannot function in "Immune Deserts" where T-cells are absent.
OAP-101 functions as the "Upstream Amplifier." We generate the T-cell clones and release the chemotactic signals required to pull them into the tumor. This converts "Excluded" tumors into "Inflamed" tumors, allowing Bispecifics and Cell Therapies to effectively engage their targets.
Expanding
Checkpoint Markets
We invite partners with PD-1/PD-L1 inhibitors to explore combination regimens. Our data suggests OAP-101 can
convert Non-Responders into Responders, significantly
expanding the addressable market for existing franchises in
indications like MSS Colorectal Cancer and PDAC.
Let’s Transform
Cancer Care Together
We welcome discussions with pharmaceutical companies and academic institutions. To explore collaboration opportunities, please contact our business development team.
Email: BD@novastra.bio